Innoviva Inc
INVA19.890USD
+0.510+2.63%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.25BMarket Cap
32.43P/E TTM
More Details of Innoviva Inc Company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Company Info
Ticker SymbolINVA
Company nameInnoviva Inc
IPO dateOct 05, 2004
CEOMr. Pavel Raifeld
Number of employees127
Security typeOrdinary Share
Fiscal year-endOct 05
Address1350 Old Bayshore Highway
CityBURLINGAME
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94010
Phone16502389600
Websitehttps://www.inva.com/
Ticker SymbolINVA
IPO dateOct 05, 2004
CEOMr. Pavel Raifeld
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Mark A. Dipaolo, Esq.
Mr. Mark A. Dipaolo, Esq.
Chairman of the Board
Chairman of the Board
130.71K
+10.18%
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Lead Independent Director
Lead Independent Director
130.71K
+10.18%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
44.10K
+11.98%
Ms. Marianne Y. Zhen, CPA
Ms. Marianne Y. Zhen, CPA
Chief Accounting Officer
Chief Accounting Officer
26.72K
-3.58%
Mr. Pavel Raifeld
Mr. Pavel Raifeld
Chief Executive Officer
Chief Executive Officer
12.60K
+8.03%
Mr. Stephen Basso
Mr. Stephen Basso
Chief Financial Officer
Chief Financial Officer
4.40K
-5.12%
Mr. Jules A. Haimovitz
Mr. Jules A. Haimovitz
Independent Director
Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Director
Director
--
--
Mr. Derek A Small
Mr. Derek A Small
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark A. Dipaolo, Esq.
Mr. Mark A. Dipaolo, Esq.
Chairman of the Board
Chairman of the Board
130.71K
+10.18%
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Lead Independent Director
Lead Independent Director
130.71K
+10.18%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
44.10K
+11.98%
Ms. Marianne Y. Zhen, CPA
Ms. Marianne Y. Zhen, CPA
Chief Accounting Officer
Chief Accounting Officer
26.72K
-3.58%
Mr. Pavel Raifeld
Mr. Pavel Raifeld
Chief Executive Officer
Chief Executive Officer
12.60K
+8.03%
Mr. Stephen Basso
Mr. Stephen Basso
Chief Financial Officer
Chief Financial Officer
4.40K
-5.12%
Revenue Breakdown
FY2025Q1
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
88.63M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.84%
The Vanguard Group, Inc.
11.36%
Renaissance Technologies LLC
7.55%
Dimensional Fund Advisors, L.P.
6.81%
Bank of Nova Scotia
5.69%
Other
55.74%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.84%
The Vanguard Group, Inc.
11.36%
Renaissance Technologies LLC
7.55%
Dimensional Fund Advisors, L.P.
6.81%
Bank of Nova Scotia
5.69%
Other
55.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.78%
Investment Advisor/Hedge Fund
36.71%
Hedge Fund
22.82%
Research Firm
6.65%
Bank and Trust
6.15%
Pension Fund
1.85%
Individual Investor
1.05%
Sovereign Wealth Fund
0.16%
Family Office
0.04%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
497
69.38M
110.09%
-7.80M
2025Q1
503
69.52M
110.75%
-9.29M
2024Q4
492
73.18M
116.75%
-6.44M
2024Q3
487
75.41M
120.47%
-5.51M
2024Q2
492
75.89M
121.41%
-5.03M
2024Q1
502
75.85M
119.80%
-4.18M
2023Q4
494
74.97M
116.88%
-1.82M
2023Q3
486
71.34M
109.51%
-8.23M
2023Q2
482
72.90M
111.23%
-6.11M
2023Q1
482
72.87M
106.90%
-10.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.24M
13.12%
-285.10K
-3.34%
Mar 31, 2025
The Vanguard Group, Inc.
6.28M
10.01%
-16.60K
-0.26%
Mar 31, 2025
Renaissance Technologies LLC
4.56M
7.26%
+295.50K
+6.93%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.66M
7.42%
-259.73K
-5.28%
Mar 31, 2025
Sarissa Capital Management, L.P.
2.82M
4.49%
-4.46M
-61.30%
Mar 31, 2025
Putnam Investment Management, L.L.C.
3.90M
6.21%
-462.44K
-10.61%
Mar 31, 2025
State Street Global Advisors (US)
2.36M
3.77%
-94.90K
-3.86%
Mar 31, 2025
American Century Investment Management, Inc.
1.68M
2.67%
+251.38K
+17.65%
Mar 31, 2025
Systematic Financial Management, L.P.
2.07M
3.3%
+42.18K
+2.08%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
